The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the American Urological Association 2025 Annual ...

Johnson & Johnson on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full ...

Johnson & Johnson is increasing its dividend for the 63rd consecutive year. This further cements the healthcare giant's ...

Johnson & Johnson JNJ reported 2.4% sales growth (2.3% in innovative medicine, 2.5% in medtech) and 2.2% adjusted EPS growth in the first quarter. Management raised reported sales growth guidance ...